Advertisement
![Picture Berlin Partner Voices Tim Huse BIH Digital Health 650x100px](/banner/berlin-partner-20240927-650-100-voices-tim-huse-bih-digital-health-startup-hotspot.jpg)
Employment/Membership › Details
Sofinnova–Nägler K: management, 202409– Partner at Sofinnova Partners before Wellington Partners + Gimv + Ventech + Atlas Venture
![]() |
Period | 2024-09-01 |
![]() |
Region | Germany |
Predecessor | Wellington Partners–Nägler K: management, 202001– Managing Partner before Gimv + Ventech + Atlas Venture | |
![]() |
Organisation | Sofinnova Partners SAS |
Organisation 2 | Wellington Partners Venture Capital GmbH | |
Group | Wellington Partners (Group) | |
![]() |
Product | venture capital |
Product 2 | LIFE SCIENCES | |
![]() |
Person | Nägler, Karl (Sofinnova 202409– Partner at S Partners before Wellington Partners + Gimv + Ventech + Atlas Venture) |
Person 2 | Seghezzi, Graziano (Sofinnova Partners 200806 Partner) | |
Sofinnova Partners. (9/10/24). "Press Release: Sofinnova Partners Appoints Karl Naegler as Partner". Paris.
Seasoned investor with 20 years of experience and a strong track record strengthens VC’s leadership in early-stage life science investments
Sofinnova Partners (“Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of Karl Naegler as Partner. This strategic hire also marks Sofinnova’s expansion into Germany, bolstering its reach and influence across Europe.
Naegler will play a key role in Sofinnova Capital, the firm’s early-stage investment strategy, established 35 years ago. His expertise strengthens the firm’s commitment to championing early-stage innovation in life sciences and enhances a well-established team of partners.
Before joining Sofinnova, Naegler was a Managing Partner at Wellington Partners Life Sciences and a Partner at Gimv, where he was instrumental in the success of several high-profile startups, from company formation to successful exit. These include Seamless Therapeutics, recently launched with a top syndicate of investors, Breath Therapeutics, a co-investment with Sofinnova, acquired by Zambon, Covagen, acquired by Johnson & Johnson, and Prosonix, acquired by Circassia Pharmaceuticals.
"We’ve known and worked with Karl for two decades and his track record speaks for itself," said Graziano Seghezzi, Managing Partner, at Sofinnova Partners. "His deep industry knowledge, impeccable reputation, and strong relationship with Sofinnova make him an exceptional addition to the team. Karl’s appointment follows the recent promotion of Anta Gkelou, from Principal to Partner, further solidifying our team of senior partners."
"Sofinnova is a world-class firm that truly leads life sciences venture capital in Europe," Naegler said. "The opportunity to be part of an investment platform spanning multiple sectors, stages and geographies, with such a high-caliber team, was an opportunity I could not pass up. I look forward to bringing my experience to bear as we build and support the most innovative companies in life sciences across Europe while reinforcing our footprint in Germany."
Naegler’s career includes key roles at Ventech and Atlas Venture. He was also a Scientific Fellow at CNRS for Neurochemistry in Strasbourg and earned his Ph.D. in Molecular Neurobiology from the Max-Delbrück-Center for Molecular Medicine in Berlin.
###
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical, and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.8 billion under management. For more information, please visit: sofinnovapartners.com.
Contacts
Bommy Lee
Head of Communications
Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
United Kingdom
Optimum Strategic Communications
Hana Malik
sofinnova@optimumcomms.com
+44 (0) 20 3882 2119
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Pierluigi Cavarai
pierluigi.cavaraiext@havaspr.com
+39 (0) 392 77 999 33
DACH
MC Services AG
Katja Arnold, Kaja Skorka
sofinnova@mc-services.eu
+49-89-210 228-0
Record changed: 2024-09-11 |
Advertisement
![Picture Consultech GmbH Secure Funding with RnD Grants 650x200px](/banner/consultech-20230614-650-200-secure-funding-rnd-grants-for-pharma-biotech.png)
More documents for Sofinnova (Group)
- [1] Sofinnova Partners. (9/10/24). "Press Release: Sofinnova Partners Appoints Karl Naegler as Partner". Paris....
- [2] Deepc GmbH. (7/24/24). "Press Release: Deepc Closes Series A Extension to Accelerate Global Deployment of Healthcare AI, Bringing Total Funding to $30m". Munich....
- [3] Cure51 SAS. (3/20/24). "Press Release: Cure51 Raises a €15 Million Seed Round to Harness the Natural Power of Cancer Survivors to Develop First-in-Class Treatments and Transform Cancer into a Curable Disease". Paris....
- [4] Disco Pharmaceuticals GmbH. (1/16/24). "Press Release: Disco Pharmaceuticals Launches as the Surfaceome Company with EUR 20 Million in Seed Financing". Cologne & Zurich....
- [5] Sofinnova Partners. (12/13/23). "Press Release: Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups". Paris....
- [6] Deepc GmbH. (3/28/23). "Press Release: Digital Medicine Pioneer, Deepc, Announces €12 Million Series A Round Led by Sofinnova Partners"....
- [7] Sofinnova Partners. (5/16/22). "Press Release: Sofinnova Partners and Apollo Form Strategic Partnership in Life Sciences". New York, NY & Paris....
- [8] Sofinnova Partners. (5/12/22). "Press Release: Sofinnova Partners Announces New Investment In Nanophoria, Developer Of An Innovative Non-viral Drug Delivery Platform". Milan....
- [9] Synthace Ltd.. (11/16/21). "Press Release: Synthace Raises $35M to Expand Access to Its Revolutionary R&D Technology for Life Changing Research". London & Boston, MA....
- [10] Sofinnova Partners. (10/19/21). "Press Release: Sofinnova Partners Raises €472 ($548) Million to Form Largest Early-stage Healthcare VC Fund in Europe". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
![Picture Consultech GmbH Secure Funding with RnD Grants 650x300px](/banner/consultech-20230614-650-300-secure-funding-rnd-grants-for-pharma-biotech.jpg)
» top